The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.
Rhonda Orr, Maria Fiatarone Singh
https://pubmed.ncbi.nlm.nih.gov/15025546/Actively Recruiting
Led by Science Valley Research Institute · Updated on 2026-08-25
96
Participants Needed
6
Research Sites
N/A
Total Duration
Researchers are exploring the use of oxandrolone, an anabolic steroid with a high anabolic to androgenic activity ratio, as a supportive treatment to improve muscle mass, strength, and functional recovery after anterior cruciate ligament ACL reconstruction surgery. This phase II, randomized, double-blind, placebo-controlled study evaluates the safety and tolerability of a subdermal bioabsorbable oxandrolone implant compared to a placebo implant over a 24-week period in men and women undergoing ACL rehabilitation. The study also examines the pharmacokinetics and serum profiles of oxandrolone delivered by this implant. Participants receive either an oxandrolone implant or a placebo implant inserted subdermally. Men assigned to the oxandrolone group receive two 200 mg implants total 400 mg, while women receive one 200 mg implant. The placebo group receives matching implants without active drug. The subdermal implant is designed to release oxandrolone directly into the bloodstream to potentially enhance muscle recovery while minimizing oral administration issues. The study includes a 24-week follow-up to monitor safety and drug delivery. Throughout the trial, participants undergo assessments including monitoring for serious adverse events and biochemical, metabolic, hormonal, and hemostasis parameters at several time points before and after implant insertion. Muscle mass, strength, and functional capacity are evaluated in an exploratory manner. Serum oxandrolone levels and pharmacokinetic measurements are collected at multiple intervals to understand drug release. The total duration of participant involvement is approximately 24 weeks, during which safety, tolerability, and exploratory efficacy outcomes are closely observed.
CONDITIONS
Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction
L
Leandro B Agati, PhD
V
Viviane Santana
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Science Valley Research Institute
Lead Sponsor
Stin Pharma
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive either the oxandrolone or placebo subdermal implant and follow a rehabilitation program.
Assessments at multiple visits including pre-insertion and at 4, 12, and 24 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rhonda Orr, Maria Fiatarone Singh
https://pubmed.ncbi.nlm.nih.gov/15025546/Abbey C Thomas, Edward M Wojtys, Catherine Brandon...
https://pubmed.ncbi.nlm.nih.gov/25683732/William A Bauman, Ann M Spungen, Joseph F Collins...
https://pubmed.ncbi.nlm.nih.gov/23689765/Alexander E Weber, Matthew C Gallo, Ioanna K Bolia...
https://pubmed.ncbi.nlm.nih.gov/34982051/Brian Wu, Dan Lorezanza, Ido Badash...
https://pubmed.ncbi.nlm.nih.gov/28840147/Science Valley Research Institute
Lead Sponsor
Stin Pharma
Collaborating Sponsor